Verrica Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Topical Delivery
      • Site Specific
    • Specialty Pharmaceuticals
  • Medical Devices
See more in Biomedtracker

Latest on Verrica Pharmaceuticals, Inc.

Scrip

Finance Watch: Biopharma IPO Queue Grows As Market Conditions Improve

 
• By Mandy Jackson

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer

Scrip

Basal Cell Carcinoma Data Steal Show In Verrica’s Q2 Earnings

 
• By Alaric DeArment

Verrica Pharmaceuticals, Inc. is hoping to tap a potentially multibillion-dollar market for the most common form of cancer in the US, basal cell carcinoma (BCC), with positive Phase II data for its i

Scrip

Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data

 
• By Ayisha Sharma

Verrica Pharmaceuticals, Inc. ’ first-in-class oncolytic peptide asset, VP-315, has shown efficacy signals in a Phase II trial in patients with basal cell carcinoma (BCC) just a month after the firm w

Pink Sheet

Supplemental Filings: Ycanth Approved For Molluscum; CDER Counter-Terrorism Head Retires; 5 Benzodiazepines Added To Schedule I

 
• By Pink Sheet Team

Welcome to another edition of Supplemental Filings, where US-based Pink Sheet reporters offer bonus, quick-hit analysis and insight we think we think you should know about, but didn't make it into ful